1. Home
  2. CDT vs STKH Comparison

CDT vs STKH Comparison

Compare CDT & STKH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CDT
  • STKH
  • Stock Information
  • Founded
  • CDT 2019
  • STKH 2018
  • Country
  • CDT United States
  • STKH Israel
  • Employees
  • CDT N/A
  • STKH N/A
  • Industry
  • CDT Biotechnology: Pharmaceutical Preparations
  • STKH Packaged Foods
  • Sector
  • CDT Health Care
  • STKH Consumer Staples
  • Exchange
  • CDT Nasdaq
  • STKH Nasdaq
  • Market Cap
  • CDT 5.3M
  • STKH 4.9M
  • IPO Year
  • CDT N/A
  • STKH 2021
  • Fundamental
  • Price
  • CDT $0.40
  • STKH $3.08
  • Analyst Decision
  • CDT
  • STKH
  • Analyst Count
  • CDT 0
  • STKH 0
  • Target Price
  • CDT N/A
  • STKH N/A
  • AVG Volume (30 Days)
  • CDT 3.1M
  • STKH 112.8K
  • Earning Date
  • CDT 05-20-2025
  • STKH 03-31-2025
  • Dividend Yield
  • CDT N/A
  • STKH N/A
  • EPS Growth
  • CDT N/A
  • STKH N/A
  • EPS
  • CDT N/A
  • STKH N/A
  • Revenue
  • CDT N/A
  • STKH $10,000.00
  • Revenue This Year
  • CDT N/A
  • STKH N/A
  • Revenue Next Year
  • CDT N/A
  • STKH N/A
  • P/E Ratio
  • CDT N/A
  • STKH N/A
  • Revenue Growth
  • CDT N/A
  • STKH N/A
  • 52 Week Low
  • CDT $0.51
  • STKH $0.60
  • 52 Week High
  • CDT $350.00
  • STKH $4.64
  • Technical
  • Relative Strength Index (RSI)
  • CDT 31.06
  • STKH 39.16
  • Support Level
  • CDT $0.37
  • STKH $2.66
  • Resistance Level
  • CDT $0.57
  • STKH $3.76
  • Average True Range (ATR)
  • CDT 0.05
  • STKH 0.41
  • MACD
  • CDT 0.01
  • STKH 0.10
  • Stochastic Oscillator
  • CDT 13.89
  • STKH 38.18

About CDT Conduit Pharmaceuticals Inc.

Conduit Pharmaceuticals Inc is a clinical-stage specialty biopharmaceutical company that was formed to facilitate the development and commercialization of clinical assets that have not been or are not being prioritized by biopharmaceutical companies to develop pharmaceutical products that meet the unmet medical needs of patients. The Company's current development pipeline includes a glucokinase activator, which is Phase II ready for autoimmune diseases including uveitis, Hashimoto's Thyroiditis, preterm labor, and renal transplant rejection. The Company's development pipeline also includes a potent, irreversible inhibitor of human Myeloperoxidase (MPO) that has the potential to treat idiopathic male infertility.

About STKH Steakholder Foods Ltd.

Steakholder Foods Ltd is engaged in transforming the alternative protein industries through its technology. The group specializes in developing and selling 3D-printing production machines, supported by proprietary premix blends, formulated from the highest-quality raw ingredients. These tools help manufacturers of all sizes efficiently produce foods that meet consumer expectations for taste, texture, and appearance and offer a safe and sustainable alternative to industrialized meat and seafood production. The company's expertise in creating alternative protein products replicating traditional meats' complex textures such as beef steaks, white fish, shrimp, and eel. It also explores the integration of cultivated cells, preparing for future advancements in food technology.

Share on Social Networks: